Search research articles
Contact Us
Filters
Showing results (21-30 of 347) with videos related to
Page
of 35
Sort By:
Future Oncology (London, England)
|
November 16, 2021
The impact of the <i>ALK</i> fusion variant on clinical outcomes in <i>EML4-ALK</i> patients with NSCLC: a systematic review and meta-analysis
Shasha Wang, Rongrong Luo, Yuankai Shi, et al.
Thoracic Cancer
|
February 17, 2022
The prognostic significance of tumor spread through air space in stage I lung adenocarcinoma
Liling Huang, Le Tang, Liyuan Dai, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|
July 28, 2022
[MUC16: The Novel Target for Tumor Therapy]
Ruyun Gao, Ning Lou, Xiaohong Han, et al.
Thoracic Cancer
|
January 15, 2016
Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports
Puyuan Xing, Junling Li, Yuankai Shi, et al.
Thoracic Cancer
|
August 29, 2018
Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis
Qiaoyun Tan, Shuxia Liu, Caixia Liang, et al.
Cancer Pathogenesis and Therapy
|
April 11, 2024
Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phase 2 clinical trial (BG01-1801)
Yuankai Shi, Gongyan Chen, Yanqiu Zhao, et al.
Leukemia Research
|
April 6, 2012
Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis
Wei Shi, Xiaohong Han, Jiarui Yao, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|
January 13, 2012
[Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis]
Junling Li, Xuezhi Hao, Yan Wang, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|
October 10, 2021
[Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib]
Liling Huang, Yan Qin, Fengyi Zhao, et al.
Oncotargets and Therapy
|
June 9, 2016
Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
Jianping Xu, Xiaoyan Liu, Sheng Yang, et al.
Page
of 35
Search research articles
Search
Showing results (21-30 of 347) with videos related to
Sort By:
Page
of 35
Future Oncology (London, England)
|
November 16, 2021
The impact of the <i>ALK</i> fusion variant on clinical outcomes in <i>EML4-ALK</i> patients with NSCLC: a systematic review and meta-analysis
Shasha Wang, Rongrong Luo, Yuankai Shi, et al.
Thoracic Cancer
|
February 17, 2022
The prognostic significance of tumor spread through air space in stage I lung adenocarcinoma
Liling Huang, Le Tang, Liyuan Dai, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|
July 28, 2022
[MUC16: The Novel Target for Tumor Therapy]
Ruyun Gao, Ning Lou, Xiaohong Han, et al.
Thoracic Cancer
|
January 15, 2016
Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports
Puyuan Xing, Junling Li, Yuankai Shi, et al.
Thoracic Cancer
|
August 29, 2018
Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis
Qiaoyun Tan, Shuxia Liu, Caixia Liang, et al.
Cancer Pathogenesis and Therapy
|
April 11, 2024
Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phase 2 clinical trial (BG01-1801)
Yuankai Shi, Gongyan Chen, Yanqiu Zhao, et al.
Leukemia Research
|
April 6, 2012
Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis
Wei Shi, Xiaohong Han, Jiarui Yao, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|
January 13, 2012
[Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis]
Junling Li, Xuezhi Hao, Yan Wang, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|
October 10, 2021
[Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib]
Liling Huang, Yan Qin, Fengyi Zhao, et al.
Oncotargets and Therapy
|
June 9, 2016
Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
Jianping Xu, Xiaoyan Liu, Sheng Yang, et al.
Page
of 35